Page 16 - DIAGEN-EN

Hematology primeFISH Products

HEMATOLOGY
PANEL

17-002 MLL (11q23) Breakapart

Up to 1-15% of cancer patients treated with KMT2A gene the most common translocations are t(4;11) and t(11;19)
rearrangements with a DNA topoisomerase II inhibitor in ALL patients, t(6;11), t(9;11) and t(11;19) in AML
develop therapy-associated leukemia (t-AML) associated patients. Overall, the finding of KMT2A
with KMT2A translocations. Translocations involving the re-arrangements in patients with acute leukemia
KMT2A gene are detected in 5-6% of all acute myeloid indicates a less favorable prognosis. However, recent
leukemias (AML) and 5-10% of all acute lymphoblastic studies suggest that the specific KMT2A translocation
leukemias (ALL). The frequency of translocations involving partner may have an impact on response to therapy
the KMT2A gene is significantly higher in infants with and overall prognosis, depending on the clinical
AML (50%) and ALL (80%). Over 30 fusion partners have concept.
been documented tor KMT2A;

BREAKAPART

RH52370 RH99291 RH52087 RH93709
5' 3'
NORMAL
Cent Tel
KMT2A

730 kb 821 kb

RE-ARRANGEMENT

11q23.3

(Not to scale)

www.diagen.com.tr References
Gindin T, et al. (2015) Hematol Oncol 33(4) 239-46.
Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
Burns et al (2018) Hematology (7th ed) Ch 64: Pathobiology of acute lymphoblastic leukemia:1005–1019.e11

16 PRODUCT CATALOGUE